Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.…
Actinium: Q3 Earnings Snapshot
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 25 employees.
The shares were at 1.050 USD on 20 November 2026, down 28.1% over 52 weeks. Its 52-week range is 0.7351 USD to 1.720 USD: the price is 39.0% below the high and 42.8% above the low.
At a market capitalisation of 33.01M USD, it trades at 2.4 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 93% for ATNM.
Actinium Pharmaceuticals reports return on equity of -432.6% and an operating margin of 26.1%.
It holds more cash than debt, a net cash position of 27.52M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.